A Phase I, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered Advanced or Metastatic Solid Tumors
Study Identifier:
MK-4716-001
CT.gov Identifier:
EudraCT Identifier:
EU Trial (CTIS) Number:
Study Contact Information:
Recruiting
Considering participating in a START clinical trial?
Study Summary
The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Non-Small Cell Lung Cancer
Solid Tumor
Phase
The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
Phase I
Sex
Female & Male
Age
18+ years
Study Drug
N/A
Study Status
Indicates the current recruitment status or the expanded access status
Recruiting
Requirements information
Inclusion criteria
- * Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Has a confirmed diagnosis of locally advanced unresectable or metastatic solid tumor
- * Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Must demonstrate presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration
- * Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Has received at least 1 prior line of systemic therapy for locally advanced unresectable or metastatic disease
- * Arm MK-4716 + Pembrolizumab: Has a confirmed diagnosis of metastatic non-small cell lung cancer
- * Arm MK-4716 + Pembrolizumab: Must demonstrate presence of KRAS alteration
- * Arm MK-4716 + Pembrolizumab: Must be untreated
- * Has measurable disease
- * Has the ability to swallow and retain oral medication The male subjects met the contraceptive requirements specified in the protocol.
- The female participants met the contraceptive requirements specified in the protocol.
- The participants (or their legally accepted representatives) have provided written informed consent for this study.
- According to RECIST 1.1 assessment, measurable lesions are present.
- Provide tumor tissue samples as required by the plan.
- AEs occurring during previous anti-tumor treatment must be resolved to grade ≤1 or at baseline.
- An ECOG fitness score of 0 or 1 within 7 days prior to assignment/randomization
- It possesses the full organ function defined in the protocol.
- It has the ability to swallow and retain oral medications.
- Applicable only to Module 1, Part 1: Subjects diagnosed with locally advanced unresectable or metastatic solid tumors must demonstrate KRAS mutation and have received at least one line of systemic therapy.
- Module 2 only: Subjects diagnosed with metastatic NSCLC must demonstrate KRAS mutation and PD-L1 positivity, and the subject must be treatment-naïve.
Exclusion criteria
- Arm MK-4716 + Pembrolizumab: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
- * Arm MK-4716 + Pembrolizumab: Has received any prior immunotherapy and was discontinued from that treatment
- * Arm MK-4716 + Pembrolizumab: Has active autoimmune disease that has required systemic treatment in the past 2 years. Hormonal supplementation (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
- * History of human immunodeficiency virus infection
- * Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
- * Has a known active central nervous system metastases and/or carcinomatous meningitis
- * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- * Has active infection requiring systemic therapy
- * Has Hepatitis B or Hepatitis C virus infection
- * History of stem cell/solid organ transplant
- * Has not adequately recovered from major surgery or has ongoing surgical complications History of HIV infection
- Those who have received systemic antitumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to randomization.
- Patients who received radiation therapy within 2 weeks prior to the start of the study intervention, or who experienced radiation-related toxicities requiring corticosteroid treatment.
- Received proton pump inhibitor or H2 receptor antagonist treatment within 14 days of the first planned study dosing date.
- Unable to comply with the prohibited drugs and washout time requirements outlined in the protocol.
- Those who received investigational drug treatment or used investigational devices within 4 weeks prior to administration of the study intervention.
- The presence of other progressive malignancies, or malignancies requiring aggressive treatment within the past two years.
- Known active CNS metastases and/or carcinomatous meningitis
- Those with a history of lung inflammation/interstitial lung disease requiring steroid treatment or currently suffering from lung inflammation/interstitial lung disease
- Active infection requiring systemic treatment
- Hepatitis B or C virus infection
- Known to have a mental illness or substance abuse disorder that may interfere with a subject's ability to cooperate with research requirements.
- Severe hypersensitivity (≥ grade 3) to the study intervention and/or any of its excipients.
- ECG average QTcF > 470 msec
- Patients with uncontrolled major cardiovascular or cerebrovascular disease within 6 months prior to the start of the study intervention.
- Lung insufficiency
- History of stem cell/solid organ transplantation
- Not yet fully recovered from major surgery or experiencing ongoing surgical complications.
- Applicable only to Module 2: Received a live or attenuated live vaccine within 30 days prior to the first dose; diagnosed with an immunodeficiency disease, or currently receiving long-term systemic steroid therapy or any other immunosuppressant therapy within 7 days prior to the first dose; previously received any immunotherapy and discontinued treatment due to a grade ≥3 irAE, or due to grade 2 myocarditis or recurrent grade 2 pulmonary inflammation; has had an active autoimmune disease requiring systemic treatment within the past 2 years; EGFR, ALK, BRAF, or ROS1 targeted therapy must not be used as primary treatment.
Clinical Study Information for Healthcare Providers
By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.
Study Locations
Location
Investigator
Status
Condition(s) Treated at Site
Location
START Madrid, Spain (FJD)
Madrid, Spain, 28040
Investigator
Victor Moreno Garcia
Status
Recruiting
Condition(s) Treated at Site
Non-Small Cell Lung Cancer
Solid Tumor